LAS1 Antibody

What is LASP1 and why is it significant in cellular research?

LASP1 (LIM and SH3 domain protein 1, also known as MLN50) is a protein that plays a critical role in the regulation of dynamic actin-based cytoskeletal activities. It forms complexes with zyxin and vasodilator-stimulated phosphoprotein (VASP) at focal adhesions, contributing to cellular motility and signaling pathways . The significance of LASP1 in research stems from its involvement in:

• Actin cytoskeleton organization

• Cell adhesion and migration

• Signal transduction

• Potential role in cancer metastasis (as suggested by its original identification as Metastatic lymph node gene 50 protein)

Understanding LASP1 function requires specific antibodies that can reliably detect and quantify the protein in various experimental contexts.

What applications are LAS1 antibodies suitable for in basic research?

LAS1 (LASP1) antibodies can be utilized in multiple research applications depending on the specific antibody formulation and validation. Common applications include:

• Western blotting (WB): For protein expression quantification and molecular weight confirmation

• Immunohistochemistry on paraffin-embedded sections (IHC-P): For localization studies in tissue samples

• Immunoprecipitation (IP): For protein-protein interaction studies

• Flow cytometry: For cellular expression analysis

For example, polyclonal antibodies like ab117806 have been validated for IHC-P, IP, and WB applications with human samples . When selecting an antibody for your research, it's essential to verify that the specific antibody has been validated for your intended application and target species.

How should researchers validate a LAS1 antibody before experimental use?

Proper validation of any antibody, including those targeting LASP1, is critical for reliable experimental results. A comprehensive validation approach should include:

• Positive and negative controls:

  • Positive: Cell lines or tissues known to express LASP1

  • Negative: LASP1 knockout samples or tissues known not to express the protein

• Antibody specificity tests:

  • Western blot analysis to confirm a single band at the expected molecular weight

  • Peptide competition assays to verify specificity

  • Multiple antibodies targeting different epitopes to confirm consistent results

• Application-specific validation:

  • For IHC: Testing different antigen retrieval methods (e.g., heat-mediated antigen retrieval with citrate buffer pH 6)

  • For WB: Optimization of antibody concentration (e.g., starting with 0.1 μg/mL)

  • For IP: Confirmation of pull-down efficiency

• Cross-reactivity assessment:

  • Testing against closely related proteins to ensure specificity

  • Validation across multiple species if cross-species reactivity is claimed

What are the optimal storage conditions for maintaining LAS1 antibody activity?

To maintain antibody activity and prevent degradation, follow these guidelines:

• Short-term storage (up to 1 week): 4°C with appropriate preservatives

• Long-term storage: -20°C or -80°C in small aliquots to avoid repeated freeze-thaw cycles

• Avoid additives that may interfere with specific applications (e.g., sodium azide for HRP-conjugated antibodies)

• Monitor appearance for signs of precipitation or contamination

• Document stability by periodically testing activity in established assays

Proper storage is particularly important for antibodies used in quantitative applications where consistent performance is essential for reliable data interpretation.

How can researchers optimize LAS1 antibody use in multiplexed immunoassays?

Multiplexed immunoassays allow simultaneous detection of multiple targets, saving valuable samples and providing comprehensive data. When incorporating LASP1 antibodies in multiplexed assays:

• Cross-reactivity mitigation:

  • Thoroughly test for cross-reactivity between all antibodies in the multiplex panel

  • Select antibodies raised in different host species to allow species-specific secondary detection

  • Consider using directly conjugated primary antibodies to avoid secondary antibody cross-reactivity

• Signal optimization:

  • Carefully titrate each antibody to determine optimal working concentration

  • Test different signal amplification strategies for low-abundance targets

  • Implement appropriate blocking protocols to reduce background

• Sequential detection strategies:

  • For challenging combinations, employ sequential rather than simultaneous detection

  • Consider tyramide signal amplification (TSA) protocols that allow antibody stripping and reapplication

  • Establish a detection sequence that minimizes epitope masking

• Validation with single-plex controls:

  • Always validate multiplexed results against single-plex controls

  • Document any signal differences between single and multiplexed formats

What approaches can resolve conflicting data when using different LAS1 antibodies?

Researchers occasionally encounter conflicting results when using different antibodies targeting the same protein. To resolve such discrepancies with LASP1 antibodies:

• Epitope mapping analysis:

  • Determine the epitope recognized by each antibody

  • Consider whether post-translational modifications might affect epitope accessibility

  • Assess whether antibodies target different LASP1 isoforms

• Comprehensive validation:

  • Implement genetic approaches (siRNA knockdown, CRISPR knockout) to verify specificity

  • Use mass spectrometry to confirm immunoprecipitation results

  • Perform peptide competition assays with specific peptide sequences

• Method-specific considerations:

  • For IHC: Compare different fixation and antigen retrieval protocols

  • For WB: Test both reducing and non-reducing conditions

  • For IP: Evaluate different lysis conditions that may affect protein conformation

• Bioinformatic analysis:

  • Check for potential cross-reactivity with homologous proteins

  • Verify antibody specificity through sequence analysis

  • Consider species-specific differences in the target protein

When publishing, clearly document which antibody was used for which experiment and provide comprehensive validation data to support your findings.

How can LAS1 antibodies be employed in studies of dynamic protein interactions?

LASP1 forms part of complexes with proteins like zyxin and VASP, making the study of its dynamic interactions crucial for understanding its function . Advanced approaches include:

• Proximity ligation assays (PLA):

  • Use pairs of antibodies against LASP1 and potential interaction partners

  • Quantify interaction signals under different cellular conditions

  • Analyze spatial distribution of interactions using high-resolution microscopy

• FRET-based interaction studies:

  • Label LASP1 antibodies and partner protein antibodies with appropriate FRET pairs

  • Measure energy transfer as an indicator of protein proximity

  • Track interactions in real-time using live-cell imaging

• Co-immunoprecipitation with crosslinking:

  • Apply membrane-permeable crosslinkers to stabilize transient interactions

  • Use LASP1 antibodies for immunoprecipitation followed by mass spectrometry

  • Compare interaction networks under different cellular conditions

• Antibody-based biosensors:

  • Develop conformation-sensitive antibodies that detect structural changes upon interaction

  • Create split-antibody complementation systems to monitor protein proximity

  • Implement microfluidic approaches for high-throughput interaction screening

What methodological approaches can minimize artifacts in immunoprecipitation experiments using LAS1 antibodies?

Immunoprecipitation (IP) with LASP1 antibodies is valuable for studying protein complexes but prone to artifacts. Advanced methodological considerations include:

• Optimized lysis conditions:

  • Test different buffer compositions to maintain native interactions

  • Consider detergent types and concentrations (e.g., NP-40 at 0.5%)

  • Adjust salt concentration to balance specificity and yield (e.g., 300 mM NaCl)

• Advanced controls:

  • Include isotype-matched non-specific antibody controls

  • Perform parallel IPs from knockout/knockdown samples

  • Consider using tagged LASP1 constructs with tag-specific antibodies as validation

• Crosslinking strategies:

  • Implement in vivo crosslinking to capture transient interactions

  • Optimize crosslinker concentration and reaction time

  • Include appropriate reversal controls

• Quantitative analysis:

  • Apply quantitative proteomics (SILAC, TMT) to distinguish specific from non-specific interactions

  • Implement statistical frameworks for assessing interaction confidence

  • Compare interaction profiles across multiple experimental conditions

• Validation through reciprocal IP:

  • Confirm key interactions by IP with antibodies against interaction partners

  • Verify complex composition through sequential IPs

  • Corroborate findings with orthogonal methods like proximity labeling

How can researchers distinguish between antibodies targeting LASP1 versus Las1/Las1L?

An important consideration is the distinction between antibodies targeting LASP1 (LIM and SH3 domain protein 1) and those targeting Las1/Las1L (involved in ribosome biogenesis):

• Sequence verification:

  • Verify the immunogen sequence used to generate the antibody

  • Confirm target specificity through sequence alignment analysis

  • Check for potential cross-reactivity between these distinct proteins

• Molecular weight confirmation:

  • LASP1 has a molecular weight of approximately 38 kDa

  • Las1/Las1L has a different molecular weight profile

  • Always confirm expected molecular weight by Western blot

• Functional validation:

  • LASP1 associates with cytoskeletal components

  • Las1/Las1L is involved in pre-rRNA processing and ribosome biogenesis

  • Validate antibody specificity through functional assays specific to each protein

• Subcellular localization:

  • LASP1 localizes primarily to focal adhesions and the cytoskeleton

  • Las1/Las1L is predominantly nucleolar/nuclear

  • Perform immunofluorescence studies to confirm proper localization pattern

What advanced biophysical methods can assess the binding properties of LAS1 antibodies?

Understanding antibody-antigen interactions at a biophysical level provides crucial insights for optimizing experimental conditions:

• Surface Plasmon Resonance (SPR):

  • Measure association/dissociation kinetics (ka, kd) and affinity constant (KD)

  • Compare binding properties across different buffer conditions

  • Assess epitope accessibility in native versus denatured states

• Bio-Layer Interferometry (BLI):

  • Determine real-time binding kinetics similar to SPR

  • Evaluate antibody performance in complex matrices

  • Screen multiple antibody variants simultaneously

• Isothermal Titration Calorimetry (ITC):

  • Measure thermodynamic parameters of binding (ΔH, ΔS, ΔG)

  • Determine stoichiometry of interaction

  • Assess contribution of enthalpy versus entropy to binding

• Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS):

  • Map epitope regions with high resolution

  • Assess conformational changes upon antibody binding

  • Identify potential allosteric effects

• Biophysics-informed computational modeling:

  • Predict antibody binding modes and specificity profiles

  • Optimize antibody sequences for improved specificity

  • Generate custom antibody variants with tailored binding properties

How can emerging microfluidics technologies enhance LAS1 antibody development and characterization?

Microfluidics offers powerful approaches to antibody development and characterization:

• Single-cell antibody discovery:

  • Encapsulate single antibody-secreting cells in droplets or hydrogels

  • Enable high-throughput screening at rates of 10^7 cells per hour

  • Create stable capture matrices around cells for concentrated antibody secretion

• Specificity profiling:

  • Simultaneously test antibodies against multiple antigens in parallel

  • Identify cross-reactivity patterns with high sensitivity

  • Generate comprehensive specificity heat maps

• On-chip affinity maturation:

  • Perform directed evolution of antibody binding domains

  • Screen large libraries for improved specificity or affinity

  • Couple with biophysics-informed computational models for rational design

• Microfluidic antibody production:

  • Culture antibody-producing cells in controlled microenvironments

  • Optimize production parameters in real-time

  • Integrate with purification and characterization workflows

What strategies can resolve non-specific binding in Western blot applications?

When experiencing non-specific binding with LASP1 antibodies in Western blotting:

• Optimization of blocking conditions:

  • Test different blocking agents (BSA, milk, commercial blockers)

  • Adjust blocking time and temperature

  • Consider specialized blockers for phosphoprotein detection

• Antibody dilution optimization:

  • Titrate primary antibody concentration (starting from 0.1 μg/mL)

  • Adjust secondary antibody concentration independently

  • Consider longer incubation times with more dilute antibody solutions

• Buffer modifications:

  • Add non-ionic detergents (0.05-0.1% Tween-20)

  • Increase salt concentration to reduce ionic interactions

  • Adjust pH to optimize specific binding

• Sample preparation refinement:

  • Test different lysis buffers to minimize protein degradation

  • Include protease and phosphatase inhibitors

  • Consider membrane transfer conditions (time, voltage, buffer composition)

• Alternative detection strategies:

  • Use highly cross-adsorbed secondary antibodies

  • Consider fluorescent detection instead of chemiluminescence

  • Implement antibody fragments (Fab, F(ab')2) to reduce background

How can researchers optimize LAS1 antibody use in immunohistochemistry applications?

For optimal results in immunohistochemistry with LASP1 antibodies:

• Antigen retrieval optimization:

  • Test heat-mediated retrieval with different buffers (citrate pH 6, EDTA pH 9)

  • Compare different retrieval methods (pressure cooker, microwave, water bath)

  • Optimize retrieval time for specific tissue types

• Signal-to-noise enhancement:

  • Implement quenching of endogenous peroxidase/phosphatase

  • Use avidin/biotin blocking for biotin-based detection systems

  • Consider tyramide signal amplification for low abundance targets

• Antibody concentration optimization:

  • Titrate antibody concentration (starting around 1 μg/mL for IHC-P)

  • Optimize primary antibody incubation time and temperature

  • Compare different detection systems (polymer, ABC, direct conjugates)

• Tissue-specific considerations:

  • Adjust protocols for different fixation methods

  • Optimize conditions for difficult tissues (e.g., adipose, bone)

  • Consider automated versus manual staining systems

• Quantification approaches:

  • Implement digital image analysis for objective scoring

  • Develop custom algorithms for subcellular localization assessment

  • Use multiplexed approaches to assess colocalization with interaction partners

What advanced techniques can improve LAS1 antibody performance in challenging samples?

For difficult samples or applications:

• Alternative fixation strategies:

  • Test different fixatives (formalin, methanol, acetone)

  • Optimize fixation time to balance structural preservation and epitope accessibility

  • Consider specialized fixatives for specific applications

• Adapter molecule approaches:

  • Implement biotinylated protein A/G to bridge primary and secondary antibodies

  • Use recombinant protein scaffolds to enhance signal

  • Apply proximity extension assays for ultra-sensitive detection

• Specialized signal amplification:

  • Implement catalyzed reporter deposition (CARD)

  • Use branched DNA technology for signal enhancement

  • Apply quantum dots for improved signal-to-noise ratio

• Tissue clearing techniques:

  • Apply CLARITY, Scale, or other clearing methods for thick tissue sections

  • Optimize antibody penetration in thick specimens

  • Combine with light-sheet microscopy for 3D imaging

• Lateral flow optimization:

  • Develop scoring systems based on colorimetric band intensity

  • Implement paired antibody approaches for improved specificity

  • Validate with quantitative laboratory methods

How can LAS1 antibodies contribute to cancer research and potential therapeutic development?

LASP1's involvement in cellular motility and cytoskeletal regulation makes it relevant to cancer research:

• Diagnostic applications:

  • Develop tissue microarray approaches to assess LASP1 expression across tumor types

  • Correlate expression patterns with clinical outcomes

  • Investigate potential as a biomarker for specific cancer subtypes

• Mechanistic studies:

  • Use antibodies to monitor LASP1 dynamics during metastatic processes

  • Study interaction with other metastasis-associated proteins

  • Investigate post-translational modifications in tumor versus normal tissue

• Therapeutic targeting approaches:

  • Develop function-blocking antibodies to inhibit LASP1 activity

  • Target LASP1-dependent signaling pathways

  • Explore antibody-drug conjugates directed at LASP1-expressing cells

• Imaging applications:

  • Create tumor-imaging agents based on LASP1 antibodies

  • Develop intraoperative imaging approaches for LASP1-expressing tumors

  • Combine with other cancer markers for multiplexed tumor characterization

What computational approaches can predict optimal LAS1 antibody epitopes for specific applications?

Advanced computational methods enhance antibody design:

• Epitope prediction algorithms:

  • Identify linear and conformational epitopes with high antigenicity

  • Predict MHC-binding peptides for potential immunogenicity

  • Analyze surface accessibility in native protein structures

• Molecular dynamics simulations:

  • Model antibody-antigen binding interactions

  • Predict conformational changes upon binding

  • Optimize binding interfaces through in silico mutations

• Biophysics-informed machine learning models:

  • Train on experimentally selected antibodies

  • Associate potential ligands with distinct binding modes

  • Enable prediction and generation of specific variants beyond experimental observations

• Structure-based design:

  • Utilize crystallographic or cryo-EM structures to guide antibody engineering

  • Optimize complementarity-determining regions (CDRs)

  • Design antibodies that recognize specific protein conformations

How can researchers apply cutting-edge protein engineering to develop next-generation LAS1 antibodies?

Protein engineering approaches for next-generation antibodies include:

• Domain fusion strategies:

  • Create bispecific antibodies targeting LASP1 and interaction partners

  • Develop intrabodies with cell-penetrating peptides for intracellular targeting

  • Engineer antibody-enzyme fusions for proximity-based applications

• Display technology optimization:

  • Implement phage display with custom antibody libraries

  • Combine with high-throughput screening methods

  • Select antibodies against defined epitopes or conformational states

• Recombinant antibody fragments:

  • Develop single-chain variable fragments (scFvs) for improved tissue penetration

  • Create antigen-binding fragments (Fabs) for reduced immunogenicity

  • Engineer nanobodies for applications requiring small binding molecules

• Affinity maturation approaches:

  • Apply directed evolution to enhance binding specificity

  • Implement computational design to optimize binding interfaces

  • Combine in vitro and in silico approaches for rational antibody engineering